Posted by Michael Wonder on 28 Aug 2025
European Commission approves Tevimbra as neo-adjuvant/adjuvant NSCLC treatment
27 August 2025 - Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in peri-operative setting in resectable non-small cell lung cancer.
BeOne Medicines today announced that the European Commission has approved Tevimbra (tislelizumab), in combination with platinum-containing chemotherapy as neo-adjuvant treatment followed by Tevimbra monotherapy as adjuvant treatment, for adult patients with resectable non-small cell lung cancer at high risk of recurrence.
